JP2022502508A5 - - Google Patents

Info

Publication number
JP2022502508A5
JP2022502508A5 JP2021542087A JP2021542087A JP2022502508A5 JP 2022502508 A5 JP2022502508 A5 JP 2022502508A5 JP 2021542087 A JP2021542087 A JP 2021542087A JP 2021542087 A JP2021542087 A JP 2021542087A JP 2022502508 A5 JP2022502508 A5 JP 2022502508A5
Authority
JP
Japan
Prior art keywords
composition according
antibody
ptcl
cell lymphoma
drug conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502508A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/054107 external-priority patent/WO2020072519A1/en
Publication of JP2022502508A publication Critical patent/JP2022502508A/ja
Publication of JP2022502508A5 publication Critical patent/JP2022502508A5/ja
Pending legal-status Critical Current

Links

JP2021542087A 2018-10-01 2019-10-01 抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法 Pending JP2022502508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739631P 2018-10-01 2018-10-01
US62/739,631 2018-10-01
PCT/US2019/054107 WO2020072519A1 (en) 2018-10-01 2019-10-01 Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy

Publications (2)

Publication Number Publication Date
JP2022502508A JP2022502508A (ja) 2022-01-11
JP2022502508A5 true JP2022502508A5 (cg-RX-API-DMAC7.html) 2022-10-11

Family

ID=68296746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542087A Pending JP2022502508A (ja) 2018-10-01 2019-10-01 抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法

Country Status (11)

Country Link
US (1) US20200102399A1 (cg-RX-API-DMAC7.html)
EP (1) EP3860658A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022502508A (cg-RX-API-DMAC7.html)
KR (1) KR20210069679A (cg-RX-API-DMAC7.html)
CN (1) CN113613678A (cg-RX-API-DMAC7.html)
AU (1) AU2019355875A1 (cg-RX-API-DMAC7.html)
CA (1) CA3114922A1 (cg-RX-API-DMAC7.html)
IL (1) IL281920A (cg-RX-API-DMAC7.html)
MX (1) MX2021003734A (cg-RX-API-DMAC7.html)
SG (1) SG11202103342QA (cg-RX-API-DMAC7.html)
WO (1) WO2020072519A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
KR20230023650A (ko) * 2020-05-13 2023-02-17 씨젠 인크. 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법
CN116964098A (zh) 2021-03-01 2023-10-27 南特生物公司 抗cd30单克隆抗体和嵌合抗原受体
WO2024145637A2 (en) * 2022-12-30 2024-07-04 The Regents Of The University Of Colorado, A Body Corporate Immunotoxin-based targeted therapy for cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2010081004A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
MA46759A (fr) * 2016-11-14 2019-09-18 Millennium Pharm Inc Dosage de conjugués anticorps-médicament anti-cd30 pour humain non adulte
KR20200080274A (ko) * 2017-11-01 2020-07-06 시애틀 지네틱스, 인크. 항-cd30 항체 약물 컨쥬게이트 요법의 부작용을 감소시키는 방법

Similar Documents

Publication Publication Date Title
AU2020222295B2 (en) Pharmaceutical combination comprising TNO155 and a PD-1 inhibitor
Gazzah et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
CN101686971B (zh) 用于治疗多发性骨髓瘤的药物产品及其用途
JP6177133B2 (ja) Cd38を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ
CN103118706B (zh) 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
JP2023508496A5 (cg-RX-API-DMAC7.html)
Minich Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma
JP2019503387A5 (cg-RX-API-DMAC7.html)
Cheng et al. Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors
JP2021518394A5 (cg-RX-API-DMAC7.html)
JP2015500822A5 (cg-RX-API-DMAC7.html)
Tuscano et al. Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
JP2021501776A5 (cg-RX-API-DMAC7.html)
WO2025061123A1 (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
JP2021523233A5 (cg-RX-API-DMAC7.html)
JP2021523158A5 (cg-RX-API-DMAC7.html)
CA2156579A1 (en) Method of treating vascular leak syndrome
JP2023500697A5 (cg-RX-API-DMAC7.html)
EP4464337A1 (en) Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents
IL315350A (en) Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
JP2022164894A (ja) 非成人のヒトに対する抗cd30抗体-薬物コンジュゲートの投与
JP2021501800A5 (cg-RX-API-DMAC7.html)
JPH01502909A (ja) 免疫毒素による人間の治療における免疫抑制
TWI832866B (zh) 醫藥組合
Goldsmith et al. Bispecific antibodies for the treatment of multiple myeloma